[阿仑单抗在俄罗斯人群高度活动性复发缓解型多发性硬化症患者中的疗效和安全性评估]
[Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population].
作者信息
Sivertseva S A, Prilenskaya A M, Popova E V, Turova E L, Volkova L I, Smagina I V, Elchaninova E Yu, Afanas'eva A I, Goncharova Z A, Markova E A, Yarosh N M, Bakhtiiarova K Z, Sherman M A, Boyko A N
机构信息
AO MSCH «Neftyanik», Tyumen, Russia.
Ural State Medical University, Yekaterinburg, Russia.
出版信息
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(9):76-82. doi: 10.17116/jnevro202312309176.
OBJECTIVE
To evaluate the severity and frequency of infusion reactions (IR) in patients with highly active relapsing-remitting multiple sclerosis (MS) In Russian population receiving alemtuzumab therapy.
MATERIAL AND METHODS
In retrospective study, we analyzed data from 50 patients with highly active relapsing-remitting multiple sclerosis (MS) from six Regional MS Centers in the Russian Federation who received two courses of alemtuzumab between 2018 and 2022.
RESULTS
Among all IRs, the most frequently reported were hives-like rashes, which were registered in 27 people, mostly of mild severity (70.6%). Headaches were the second most common IR, observed in 17 patients (34%). When comparing the group of patients who underwent music therapy (MT) with those who received alemtuzumab therapy without MT, no statistically significant difference was found in the frequency and severity of IRs.
CONCLUSION
All patients experienced IRs of varying degrees of severity. A decrease in the score on the EDSS disability scale was noted. MT did not affect the occurrence or severity of IRs.
目的
评估俄罗斯接受阿仑单抗治疗的高度活动性复发缓解型多发性硬化症（MS）患者中输注反应（IR）的严重程度和发生率。
材料与方法
在一项回顾性研究中，我们分析了来自俄罗斯联邦六个地区性MS中心的50例高度活动性复发缓解型多发性硬化症（MS）患者的数据，这些患者在2018年至2022年期间接受了两个疗程的阿仑单抗治疗。
结果
在所有输注反应中，最常报告的是荨麻疹样皮疹，有27人出现，大多为轻度（70.6%）。头痛是第二常见的输注反应，17例患者（34%）出现。将接受音乐疗法（MT）的患者组与未接受MT的阿仑单抗治疗患者组进行比较时，输注反应的发生率和严重程度未发现统计学上的显著差异。
结论
所有患者均经历了不同程度严重的输注反应。扩展残疾状态量表（EDSS）评分有所下降。音乐疗法未影响输注反应的发生或严重程度。
Zotero 插件